You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

Elapegademase-lvlr - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for elapegademase-lvlr
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:1
Suppliers: see list1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for elapegademase-lvlr Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for elapegademase-lvlr Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for elapegademase-lvlr Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Elapegademase-lvlr

Introduction to Elapegademase-lvlr

Elapegademase-lvlr, marketed as Revcovi, is an enzyme replacement therapy developed by Leadiant Biosciences for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. The FDA approved Revcovi on October 5, 2018, marking a significant milestone in the treatment of this ultra-rare and inherited disorder[2][5].

Market Size and Growth Projections

The global elapegademase-lvlr market is anticipated to experience steady growth over the forecast period. According to market research, the market is projected to reach approximately $19 million by 2030, growing from an estimated $16 million in 2024 at a Compound Annual Growth Rate (CAGR) of 3.6%[4].

Segmentation and Market Analysis

The market for elapegademase-lvlr is segmented based on several key factors:

Application

The market is segmented into pediatric and adult applications. ADA-SCID is more prevalent in pediatric patients, but the drug's approval for adult patients expands its market reach[2].

Product

The primary product in this market is Revcovi, with other related products like Strimvelis and Adagen also being considered in broader market analyses[1].

Geography

The market is geographically divided into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. These regions vary in terms of market size, growth rates, and regulatory environments[1].

Drivers and Restraints

Drivers

  • Increasing Awareness and Diagnosis: Improved diagnostic techniques and increased awareness of ADA-SCID are driving the demand for elapegademase-lvlr.
  • Regulatory Approvals: The FDA approval of Revcovi has been a significant driver, providing a clear regulatory pathway for the drug's use.
  • Comprehensive Treatment Support: Leadiant Biosciences' efforts in educating physicians, navigating reimbursement, and offering patient assistance programs have enhanced market penetration[2][5].

Restraints

  • Ultra-Rare Disease: ADA-SCID is an extremely rare condition, limiting the market size and potential for widespread adoption.
  • High Development Costs: The development and production of biologic drugs like elapegademase-lvlr are costly, which can impact pricing and accessibility.
  • Side Effects and Precautions: The drug comes with warnings and precautions, such as the risk of thrombocytopenia, which can affect its adoption rate[2].

Competitive Landscape

The competitive landscape for elapegademase-lvlr is characterized by a few key players:

Leadiant Biosciences

Leadiant Biosciences is the primary company behind Revcovi. Their commitment to providing innovative therapies for rare diseases has been instrumental in bringing this drug to market[2][5].

Orchard Therapeutics

While not directly involved in the production of elapegademase-lvlr, Orchard Therapeutics is another player in the rare disease treatment space, and their activities can influence the broader market dynamics[3].

Financial Performance and Projections

Revenue Forecast

The market is expected to grow from $16 million in 2024 to $19 million by 2030, indicating a steady increase in revenue over the forecast period[4].

Company Financials

Leadiant Biosciences, as the main player, has seen significant investment and commitment to bringing Revcovi to market. The company's financial performance is closely tied to the success of this drug, with ongoing clinical studies and post-marketing commitments aimed at ensuring its long-term viability[5].

Impact of External Factors

COVID-19 Pandemic

The COVID-19 pandemic had a mixed impact on the market. While it caused temporary disruptions in clinical trials and operations, companies like Leadiant Biosciences and Orchard Therapeutics adapted to remote working practices, minimizing long-term financial impacts[3].

Mechanism of Action and Clinical Studies

Elapegademase-lvlr works by replacing the deficient ADA enzyme, which is crucial for purine metabolism. Clinical studies, such as the 1-way crossover study in the United States and the single-arm clinical study in Japan, have demonstrated the safety, efficacy, and pharmacokinetics of the drug in patients with ADA-SCID[2].

Warnings and Precautions

The drug is administered via intramuscular injection and should be used with caution in patients with thrombocytopenia. Severe thrombocytopenia is a contraindication for its use[2].

Market Outlook and Trends

The market outlook for elapegademase-lvlr is positive, driven by the increasing need for effective treatments for ADA-SCID. Here are some key trends:

Growth Drivers

  • Advancements in Diagnostic Techniques: Improved diagnostic methods will lead to more accurate and timely diagnoses, increasing the demand for the drug.
  • Expanding Patient Base: As awareness and diagnosis rates improve, the patient base is expected to expand, driving market growth[1].

Challenges and Opportunities

  • Regulatory Environment: Navigating regulatory approvals and ensuring compliance will remain crucial for market expansion.
  • Competition from Emerging Therapies: The potential emergence of new therapies could pose a challenge, but it also presents opportunities for innovation and collaboration[1].

Key Players and Their Strategies

Leadiant Biosciences

Leadiant Biosciences is committed to providing comprehensive treatment support, including disease state education, reimbursement navigation, and patient assistance programs. Their post-marketing commitment includes ongoing clinical studies to monitor the drug's efficacy and safety[2][5].

Conclusion

The market for elapegademase-lvlr is poised for significant growth, driven by increasing awareness, regulatory approvals, and the commitment of key players like Leadiant Biosciences. Despite the challenges associated with ultra-rare diseases and high development costs, the financial trajectory of this market indicates a promising future.

Key Takeaways

  • Market Growth: The global elapegademase-lvlr market is expected to grow at a CAGR of 3.6% from 2024 to 2030.
  • Key Players: Leadiant Biosciences is the primary player, with a strong commitment to providing innovative therapies.
  • Regulatory Approvals: FDA approval in 2018 has been a significant driver for the market.
  • Clinical Studies: Ongoing studies are crucial for monitoring the drug's efficacy and safety.
  • Market Segmentation: The market is segmented by application, product, and geography.

Frequently Asked Questions (FAQs)

Q: What is elapegademase-lvlr used for? A: Elapegademase-lvlr, marketed as Revcovi, is used for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients[2].

Q: Who is the primary manufacturer of elapegademase-lvlr? A: The primary manufacturer of elapegademase-lvlr is Leadiant Biosciences[2][5].

Q: What is the projected market size of elapegademase-lvlr by 2030? A: The global elapegademase-lvlr market is projected to reach approximately $19 million by 2030[4].

Q: What are the key drivers of the elapegademase-lvlr market? A: Key drivers include increasing awareness and diagnosis of ADA-SCID, regulatory approvals, and comprehensive treatment support provided by Leadiant Biosciences[1][2].

Q: What are the potential challenges for the elapegademase-lvlr market? A: Challenges include the ultra-rare nature of ADA-SCID, high development costs, and potential side effects such as thrombocytopenia[2].

Cited Sources

  1. Market Research Intellect - Global Elapegademase-lvlr Market Size Forecast[1].
  2. Pharmacy Times - Revcovi: A New Treatment Option for ADA-SCID[2].
  3. Orchard Therapeutics plc - Annual Report[3].
  4. Valuates Reports - Elapegademase-lvlr Market Size[4].
  5. BioSpace - FDA Approves Revcovi™, a New Enzyme Replacement Therapy[5].
Last updated: 2024-12-18

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.